(Q42202640)

18 October 2017

title

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study (English)

1 reference

18 October 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

Gideon M. Hirschfield

2

1 reference

18 October 2017

1

Christophe Hézode

1 reference

18 October 2017

23

Stefan Zeuzem

1 reference

18 October 2017

29

Megan Wind-Rotolo

1 reference

18 October 2017

Nina Weis

14

0 references

Imam Waked

Imam Waked

9

0 references

Ola Weiland

Ola Weiland

20

0 references

Maurizia R Brunetto

Maurizia R Brunetto

21

0 references

Stanislas Pol

13

Stanislas Pol

1 reference

18 October 2017

25

Mark Sulkowski

1 reference

18 October 2017

Wayne Ghesquiere

3

1 reference

18 October 2017

William Sievert

4

1 reference

18 October 2017

Maribel Rodriguez-Torres

5

1 reference

18 October 2017

Stephen D Shafran

6

1 reference

18 October 2017

Paul J Thuluvath

7

1 reference

18 October 2017

Harvey A Tatum

8

1 reference

18 October 2017

Gamal Esmat

10

1 reference

18 October 2017

Eric J Lawitz

11

1 reference

18 October 2017

Vinod K Rustgi

12

1 reference

18 October 2017

Paul J Pockros

15

1 reference

18 October 2017

Marc Bourlière

16

1 reference

18 October 2017

Lawrence Serfaty

17

1 reference

18 October 2017

John M Vierling

18

1 reference

18 October 2017

Michael W Fried

19

1 reference

18 October 2017

Gregory T Everson

22

1 reference

18 October 2017

Paul Y Kwo

24

1 reference

18 October 2017

Norbert Bräu

26

1 reference

18 October 2017

Dennis Hernandez

27

1 reference

18 October 2017

Fiona McPhee

28

1 reference

18 October 2017

Zhaohui Liu

30

1 reference

18 October 2017

Stephanie Noviello

31

1 reference

18 October 2017

Eric A Hughes

32

1 reference

18 October 2017

Philip D Yin

33

1 reference

18 October 2017

Steven Schnittman

34

1 reference

18 October 2017

language of work or name

English

0 references

publication date

30 July 2014

1 reference

18 October 2017

1 reference

18 October 2017

volume

64

1 reference

18 October 2017

issue

6

1 reference

18 October 2017

page(s)

948-956

1 reference

The global health burden of hepatitis C virus infection

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

The global burden of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Hepatitis C virus genotype 4 therapy: progress and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307498

10.1136/GUTJNL-2014-307498

21 January 2018

Identifiers

DOI

1 reference

18 October 2017

1 reference